重组水疱性口炎病毒埃博拉疫苗(rVSVΔG-ZEBOV-GP)免疫后对扎伊尔埃博拉糖蛋白及病毒载体蛋白的细胞与体液免疫
32名参与者接种rVSVΔG-ZEBOV-GP疫苗前及接种后6个月内采集血清和外周血单个核细胞,检测ZEBOV-GP、VSV-I M蛋白和NP的抗体、记忆B细胞及T细胞反应。接种后ZEBOV-GP IgG光密度在既往接种和未接种ZEBOV疫苗者中均升高,仅未接种者ZEBOV-GP IgM升高;6个月时所有参与者均可检出ZEBOV-GP特异性IgG分泌记忆B细胞,对VSV-I蛋白的T细胞反应存在但强度低。
要点
- 接种后ZEBOV-GP IgG光密度在ZEBOV疫苗未接种和既往接种者中均升高。
- 仅ZEBOV疫苗未接种者接种后ZEBOV-GP IgM光密度升高。
- 6个月时所有参与者均可检出ZEBOV-GP特异性IgG分泌记忆B细胞。
核心结论
- rVSVΔG-ZEBOV-GP疫苗在ZEBOV疫苗未接种和既往接种者中均诱导对ZEBOV糖蛋白的稳健体液和记忆B细胞反应,并可产生载体导向的T细胞免疫。
研究设计与样本
- 前瞻性多中心研究(ClinicalTrials.gov NCT02788227),纳入32名参与者,接种前及接种后至6个月采集血清和外周血单个核细胞。
- 11/32(34.4%)参与者入组前曾接种另一种研究性ZEBOV疫苗,21/32(65.6%)为ZEBOV疫苗未接种者。
- 采用ELISA、ELISpot和流式细胞术分别检测抗体、IgG分泌记忆B细胞和T细胞反应。
主要发现
- ZEBOV疫苗未接种和既往接种者接种后ZEBOV-GP IgG光密度均升高,仅未接种者ZEBOV-GP IgM光密度升高。
- 少数参与者出现对VSV-I M蛋白和NP的短暂IgM和IgG抗体反应。
- 接种后6个月所有参与者均可检出ZEBOV-GP特异性IgG分泌记忆B细胞,对VSV-I蛋白的IgG分泌记忆B细胞中位数无变化。
- 对ZEBOV-GP的T细胞反应在ZEBOV疫苗既往接种者与未接种者之间存在差异。
- 观察到对VSV-I M蛋白和VSV-I NP的T细胞反应,但强度低。
局限性
- 需进一步研究以理解既存载体免疫和靶抗原免疫对rVSVΔG-ZEBOV-GP及其他rVSV载体疫苗加强剂次反应的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While effective at preventing Zaire ebolavirus (ZEBOV) disease, cellular immunity to ZEBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing ZEBOV glycoprotein (rVSVΔG-ZEBOV-GP) vaccine remain poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies, IgG-producing memory B cells (MBCs), and T cell reactivity to ZEBOV glycoprotein (ZEBOV-GP), vesicular stomatitis virus-Indiana strain (VSV-I) matrix (M) protein, and VSV-I nucleoprotein (NP) were measured using ELISA, ELISpot, and flow cytometry, respectively. 11/32 (34.4%) participants previously received a different investigational ZEBOV vaccine prior to enrollment and 21/32 (65.6%) participants were ZEBOV vaccine naïve. Both ZEBOV vaccine naïve and experienced participants had increased ZEBOV-GP IgG optical densities (ODs) post-rVSVΔG-ZEBOV-GP vaccination while only ZEBOV vaccine naïve participants had increased ZEBOV-GP IgM ODs. Transient IgM and IgG antibody responses to VSV-I M protein and NP were observed in a minority of participants. All participants had detectable ZEBOV-GP specific IgG-producing MBCs by 6 months post-vaccination while no changes were observed in the median IgG-producing MBCs to VSV-I proteins. T cell responses to ZEBOV-GP differed between ZEBOV vaccine experienced and ZEBOV vaccine naïve participants. T cell responses to both VSV-I M protein and VSV-I NP were observed, but were of a low magnitude. The rVSVΔG-ZEBOV-GP vaccine elicits robust humoral and memory B cell responses to ZEBOV glycoprotein in both ZEBOV vaccine naïve and experienced individuals and can generate vector-directed T cell immunity. Further research is needed to understand the significance of pre-existing vector and target antigen immunity on responses to booster doses of rVSVΔG-ZEBOV-GP and other rVSV-vectored vaccines.
引用
- Raabe V, Lai L, Morales J, et al. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP). Vaccine. 2023. PMID: 36725433. doi:10.1016/j.vaccine.2023.01.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。